Komori
KYORIN Pharmaceutical (4569) · PolicyAdvanced

Reviewing the Rationale for and Reducing Cross-Shareholdings

First written in FY2019. 3 of 7 entries say "Advanced", first in FY2023. Latest entry: FY2026.

7entries
8years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2019 – FY2020AdvancedFY2023 – FY20252019: 120192020: 120202021: 020212022: 020222023: 120232024: 120242025: 120252026: 22026
Same theme, other companies
Review of the Rationale for Holding Strategic ShareholdingsA theme 1258 companies write about · 1 as a headwind · 666 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 1262 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「In fiscal 2025, the company sold part of its holdings by mutual agreement.」

    Under its policy of reviewing the rationale for and reducing strategic shareholdings, the company also sold part of its holdings in fiscal 2025. It continues to target reducing strategic shareholdings to less than 10% of consolidated net assets by fiscal 2030.
  2. 2026-05-28RestatedGeneral Meetings of Shareholders

    「Based on this approach, we set a target of reducing policy-held shares to less than 10% of consolidated net assets by FY2030.」

    The quantitative deadline-based target of reducing policy-held shares to less than 10% of consolidated net assets by FY2030 was reiterated.
  3. FY2025RaisedAnnual report

    「Based on this approach, we set a target of reducing policy-held shares to less than 10% of consolidated net assets by FY2030.」

    Regarding its policy of reducing strategic shareholdings, the company set a new quantified, time-bound target of reducing them to less than 10% of consolidated net assets by fiscal 2030.
  4. FY2024AdvancedAnnual report

    「For shares deemed to have limited strategic value, the company engages in dialogue with the investee companies from time to time and seeks to reduce its holdings. In fiscal 2023, it sold part of its holdings by mutual agreement.」

    Under its policy of reviewing the rationale for and reducing strategic shareholdings, the company sold 1 stock in fiscal 2023 for ¥1,976 million.
  5. FY2023AdvancedAnnual report

    「For shares deemed to have limited strategic value, the company engages in dialogue with the investee companies from time to time and seeks to reduce its holdings. In fiscal 2022, it sold part of its holdings by mutual agreement.」

    Under its policy of reviewing the rationale for and reducing strategic shareholdings, the company sold part of its holdings by mutual agreement in fiscal 2022.
  6. FY2020No sales during the fiscal yearAnnual report

    「For shares deemed to have limited strategic value, the company engages in dialogue with the investee companies from time to time and seeks to reduce its holdings. In fiscal 2019, it did not sell any of its holdings.」

    The company continues to review the rationale for and pursue the reduction of strategic shareholdings, but states that it made no sales in fiscal 2019.
  7. FY2019First statedAnnual report

    「For shares that we determine have little significance to our holdings, we engage in dialogue with the investee company before working to reduce our holdings. During the fiscal year, we sold 4 issues.」

    The Company newly stated that it reviews the rationale for cross-shareholdings based on transactions, dividends and other factors and reduces holdings considered to have little significance.
Moved together

"Expanding Product Offerings in Priority Areas through Active Licensing" moved the same way as this thread, in the same document, in 3 of its 7 moves.

322★123
  1. ★This thread
  2. 1Expanding Product Offerings in Priority Areas through Active Licensing3×
  3. 2Strengthening the Ultra-Fast Gene Quantification Instrument Business through the Acquisition of Jitas2×
  4. 3Decline in Upfront License Fees and Royalty Income2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet. It last moved in the General Meetings of Shareholders of 2026-05-28: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Reviewing the Rationale for and Reducing Cross-Shareholdings | KYORIN Pharmaceutical Co.,Ltd. (4569) | Komori